Tuesday, May 04, 2010 11:13:07 AM
Vivakor Receives Reseller Distribution Agreement From VWR International LLC, a Multi Billion Dollar Global Laboratory Supply and Distribution Company, for Its VivaThermic Vials
May 3, 2010 1:36:00 PM
2010 GlobeNewswire, Inc.
CORALVILLE, Iowa, May 3, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) announced today that it has received a reseller offer agreement from VWR LLC, a multi-billion dollar global laboratory supply and distribution company, for Vivakor's VivaThermic Vials. Vivakor's VivaThermic vials improve cryopreservation of sensitive cell types such as human stem cells.
Vivakor 's Chief Executive Officer and Chief Scientific Officer, Dr. Tannin Fuja, stated, "We are very pleased to do business with VWR International LLC as this agreement has been the culmination of over six months of review and evaluation of the VivaThermic products. VWR is a premier leader in distribution of laboratory products to biotech, academic and pharmaceutical research markets." As global demand for products supporting stem cell related markets intensifies, the potential market size for our VivaThermic vials has increased the potential revenue projections are targeted to reach in excess of $20 million annually. Dr. Fuja continued, "The estimated growth of this market will accelerate with continued private and public support for life-saving stem cell therapies and the necessary research to discover them."
About Vivakor, Inc.
Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
About VWR International LLC.
VWR International, LLC, headquartered in West Chester, Pennsylvania, is a global laboratory supply and distribution company with worldwide sales in excess of $3.5 billion in 2009. VWR enables the advancement of the world's most critical research through the distribution of a highly diversified product line to most of the world's top pharmaceutical and biotech companies, as well as industrial, educational and governmental organizations. With 150 years of industry experience, VWR offers a well-established distribution network that reaches thousands of specialized labs and facilities spanning the globe. VWR has 6,500 associates around the world working to streamline the way researchers across North America, Europe, and Asia stock and maintain their labs. In addition, VWR further supports its customers by providing onsite services, storeroom management, product procurement, supply chain systems integration and technical services.
For more information on VWR please visit www.vwr.com
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
CONTACT: Vivakor, Inc.
Investor Relations
c/o IME Advisors
(888) 648-8485
Recent VIVK News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/18/2024 09:25:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 01:45:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:28:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 09:25:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:41:40 AM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 05/23/2024 01:25:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 09:29:33 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 08:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:06:58 PM
- Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law Firm • PR Newswire (US) • 03/15/2024 04:53:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:24 PM
- Socially Responsible Energy Operator Announces Planned Acquisition, Sending Shares Higher • AllPennyStocks.com • 03/04/2024 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 10:10:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 10:17:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/09/2024 10:11:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:44:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 10:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:30:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/12/2023 10:26:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:45:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/24/2023 10:10:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:30:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:41:29 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/17/2023 04:20:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:10 PM
FEATURED North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • Jul 18, 2024 9:00 AM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM